Harrison M. Penrose

Harrison M. Penrose

Auto-generated profile, based on publicly available information

Harrison M. Penrose

Department of Pathology and Laboratory Medicine, Tulane University, New Orleans, Louisiana

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2018 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
RSRyousuke Satou
Ryousuke Satou
HPHarrison Penrose
Harrison Penrose
LNL. Gabriel Navar
L. Gabriel Navar

1 January 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HPHarrison Penrose
Harrison Penrose
SHSandra Heller
Sandra Heller
CCChloe Cable
Chloe Cable
RMRania Makboul
Rania Makboul
GCGita Chadalawada
Gita Chadalawada
SSSuzana Savkovic
Suzana Savkovic

9 February 2017 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SHSandra Heller
Sandra Heller
HPHarrison M. Penrose
Harrison M. Penrose
CCChloe Cable
Chloe Cable
DBDebjani Biswas
Debjani Biswas
HNHani Nakhoul
Hani Nakhoul
SSSuzana Savkovic
Suzana Savkovic
Intestinal inflammation is associated with low levels of mucosal ATP, highlighting the importance of mitochondrial function associated with ATP production in the pathophysiology of the disease. In the inflamed colon of humans and mice, we found decreased levels of mitochondrial complex cytochrome c oxidase I/IV and lower ATP levels. Thus, we generated colonic ρ 0 cells with reduced mitochondrial function linked to ATP production by selective depletion of mitochondrial DNA. In these cells, RNA sequencing revealed a substantial number of differentially expressed transcripts, among which 240 belonged to inflammatory pathways activated in human inflamed colon and TNF‐α‐treated cells (false discovery rate < 0.05). TNF‐α treatment of colonic ρ 0 cells augmented IL‐8 expression by 9‐fold (P < 0.01) via NF‐κB compared to TNF‐α‐treated control. Moreover, reduced mitochondrial function facilitated TNF‐α‐mediated NF‐κB luciferase promoter activity as a result of lowered inhibitory IκBα (nuclear factor of κ light polypeptide gene enhancer in B‐cell inhibitor, α), leading to elevated NF‐κB. In cells with reduced mitochondrial function, TNF‐α facilitated AMPKα2 activation by 8‐fold (P < 0.01), which was involved in NF‐κB‐dependent IL‐8 expression. Last, in human and mouse colon, anti‐TNF‐α treatment restored reduced mitochondria‐dependent inflammation. We propose that selective targeting of this novel mechanism provides new treatment opportunities for intestinal inflammation.—Heller, S., Penrose, H. M., Cable, C., Biswas, D., Nakhoul, H., Baddoo, M., Flemington, E., Crawford, S. E., Savkovic, S. D. Reduced mitochondrial activity in colonocytes facilitates AMPKα2‐dependent inflammation. FASEB J. 31, 2013–2025 (2017). www.fasebj.org

25 January 2017 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
HPHarrison M. Penrose
Harrison M. Penrose
SHSandra Heller
Sandra Heller
CCChloe Cable
Chloe Cable
HNHani Nakhoul
Hani Nakhoul
MBMelody Baddoo
Melody Baddoo
SSSuzana Savkovic
Suzana Savkovic
Obesity, an immense epidemic affecting approximately half a billion adults, has doubled in prevalence in the last several decades. Epidemiological data support that obesity, due to intake of a high-fat, western diet, increases the risk of colon cancer; however, the mechanisms underlying this risk remain unclear. Here, utilizing next generation RNA sequencing, we aimed to determine the high-fat diet (HFD) mediated expression profile in mouse colon and the azoxymethane/dextran sulfate sodium model of colon cancer. Mice on HFD had significantly higher colonic inflammation, tumor burden, and a number of differentially expressed transcripts compared to mice on regular diet (RD). We identified 721 transcripts differentially expressed in mouse HFD colon that were in a shared pattern with colonic tumors (RD and HFD). Importantly, in mouse colon, HFD stimulated an expression signature strikingly similar to human colon cancer, especially those with inflammatory microsatellite instability. Furthermore, pathway analysis of these transcripts demonstrated their association with active inflammation and colon cancer signaling, with leptin and Wnt as the top two transcripts elevated in mouse HFD colon shared with tumors. Moreover, in mouse colon, HFD-stimulated tumorigenic Wnt pathway activation was further validated by upregulation of β-catenin transcriptional targets. Finally, in human colon cancer, upregulation of leptin pathway members was shown with a large network of dysregulated transcripts being linked with worse overall survival.

1 December 2016 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
MKMoorthy Krishnan
Moorthy Krishnan
HPHarrison M. Penrose
Harrison M. Penrose
NSNilay N. Shah
Nilay N. Shah
RMRonald R. Marchelletta
Ronald R. Marchelletta
DMDeclan McCole
Declan McCole
Background. VSL#3 is a probiotic compound that has been used in the treatment of inflammatory bowel disease. T-cell protein tyrosine phosphatase (TCPTP) is the

1 November 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
HPHarrison M. Penrose
Harrison M. Penrose
RMRonald R. Marchelletta
Ronald R. Marchelletta
MKMoorthy Krishnan
Moorthy Krishnan
DMDeclan McCole
Declan McCole
The gene locus encoding protein-tyrosine phosphatase non-receptor type 2 (PTPN2) has been associated with inflammatory bowel disease. Expression of the PTPN2 gene product, T cell protein-tyrosine phosphatase (TCPTP), in intestinal epithelial cells has been shown to play an important role in the protection of epithelial barrier function during periods of inflammation by acting as a negative regulator of the proinflammatory cytokine IFN-γ. Therefore, agents that increase the activity of TCPTP are of general interest as modifiers of inflammatory signaling events. A previous study demonstrated that the small molecule spermidine is a selective activator of TCPTP in vitro. The aim of this study was to investigate whether activation of TCPTP by spermidine was capable of alleviating IFN-γ-induced, proinflammatory signaling and barrier dysfunction in human intestinal epithelial cells. Studies revealed that treatment of T84 and HT29/cl.19A colonocytes with spermidine increased both TCPTP protein levels and enzymatic activity, correlating with a decrease in the phosphorylation of the signal transducers and activators of transcription 1 and 3, downstream mediators of IFN-γ signaling, upon coadministration of spermidine to IFN-γ-treated cells. On a functional level, spermidine protected barrier function in the setting of inflammation, restricting the decrease in transepithelial electrical resistance and the increase in epithelial permeability induced by IFN-γ in coincubation experiments. These data implicate spermidine as a potential therapeutic agent to treat conditions associated with elevated IFN-γ signaling and a faulty mucosal barrier.